TITLE

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

PUB. DATE
January 2012
SOURCE
BMC Research Notes;2012, Vol. 5 Issue 1, p162
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents an observational study, that investigates clinical features, treatment and prognosis associated with Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer (MBC), in Morocco. HER2 refers to the human epidermal growth factor receptor. It is concluded that progression-free survival (PFS) is extended by Bevacizumab based chemotherapy in first line treatment of HER2 negative MBC, and particularly in combination with Taxanes. The background, findings, and conclusion, of the study are discussed in detail.
ACCESSION #
75046374

 

Related Articles

  • Newer Therapies for the Treatment of Metastatic Breast Cancer: a Clinical Update. MOHAN, ANJANA; PONNUSANKAR, S. // Indian Journal of Pharmaceutical Sciences;May/Jun2013, Vol. 75 Issue 3, p251 

    Breast cancer is the foremost common malignancy among the female population around the world. Female breast cancer incidence rates have increased since 1980, slowed in 1990, the rate of increase have leveled off since 2001. In spite of the advances in the early detection, treatment, surgery and...

  • Newer Therapies for the Treatment of Metastatic Breast Cancer: a Clinical Update. MOHAN, ANJANA; PONNUSANKAR, S. // Indian Journal of Pharmaceutical Sciences;May/Jun2013, Vol. 75 Issue 3, p251 

    Breast cancer is the foremost common malignancy among the female population around the world. Female breast cancer incidence rates have increased since 1980, slowed in 1990, the rate of increase have leveled off since 2001. In spite of the advances in the early detection, treatment, surgery and...

  • Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Rakha, E A; Tan, P H; Varga, Z; Tse, G M; Shaaban, A M; Climent, F; van Deurzen, C H M; Purnell, D; Dodwell, D; Chan, T; Ellis, I O // British Journal of Cancer;1/20/2015, Vol. 112 Issue 2, p283 

    Background:Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). However, current data on MBC are largely derived from small...

  • Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Petrelli, F.; Barni, S. // Medical Oncology;Dec2012, Vol. 29 Issue 4, p2586 

    High levels of human epidermal growth receptor 2 (HER2) expression are associated with recurrence and death in breast cancer (BC) patients. We have performed a systematic review and meta-analysis in order to evaluate the prognosis for HER2+ pT1a-bN0M0 BC patients. A search of PubMed and Embase...

  • Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Chow, L W-C; Xu, B; Gupta, S; Freyman, A; Zhao, Y; Abbas, R; Vo Van, M-L; Bondarenko, I // British Journal of Cancer;5/21/2013, Vol. 108 Issue 10, p1985 

    Introduction:Neratinib is a potent irreversible pan-ErbB tyrosine kinase inhibitor that has demonstrated antitumour activity and an acceptable safety profile in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer and other solid tumours.Methods:This was a phase...

  • Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Layman, Rachel; Ruppert, Amy; Lynn, Melinda; Mrozek, Ewa; Ramaswamy, Bhuvaneswari; Lustberg, Maryam; Wesolowski, Robert; Ottman, Susan; Carothers, Sarah; Bingman, Anissa; Reinbolt, Raquel; Kraut, Eric; Shapiro, Charles // Cancer Chemotherapy & Pharmacology;May2013, Vol. 71 Issue 5, p1183 

    Purpose: Triple negative breast cancers (TNBC) frequently have high epidermal growth factor receptor (EGFR) expression and are sensitive to DNA-damaging agents. Improved therapies are needed for this aggressive malignancy. Patients and methods: We performed a phase I trial of bendamustine and...

  • Texture analysis on MR images helps predicting non-response to NAC in breast cancer. Michoux, N.; Van den Broeck, S.; Lacoste, L.; Fellah, L.; Galant, C.; Berlière, M.; Leconte, I. // BMC Cancer;Aug2015, Vol. 15 Issue 1, p1 

    Background: To assess the performance of a predictive model of non-response to neoadjuvant chemotherapy (NAC) in patients with breast cancer based on texture, kinetic, and BI-RADS parameters measured from dynamic MRI. Methods: Sixty-nine patients with invasive ductal carcinoma of the breast who...

  • First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Miles, D. W.; Diéras, V.; Cortés, J.; Duenne, A.-A.; Yi, J.; O'Shaughnessy, J. // Annals of Oncology;Nov2013, Vol. 24 Issue 11, p2773 

    Background Bevacizumab has consistently demonstrated improved progression-free survival (PFS) and response rate when combined with first-line chemotherapy for HER2-negative metastatic breast cancer (mBC). However, the lack of a significant overall survival (OS) difference continues to attract...

  • Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review. Kandula, Mahesh; Kumar Ch, Kalyan; Raju YS, Ammi // World Journal of Oncology;2013, Vol. 4 Issue 3, p137 

    Tripple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics